Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

被引：0
|
作者：
Pilotto, Sara [1 ]
Bria, Emilio [1 ]
机构：
[1] Univ Verona, Azienda Osped Univ Integrata, GB Rossi Acad Hosp, Med Oncol, Verona, Italy
来源：
LUNG CANCER MANAGEMENT | 2013年 / 2卷 / 02期
关键词：
D O I：
10.2217/LMT.12.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：89 / 92
页数：4
相关论文
共 50 条
  • [41] Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Ma, Jie-Tao
    Guo, Yi-Jia
    Song, Jun
    Sun, Li
    Zhang, Shu-Ling
    Huang, Le-Tian
    Jing, Wei
    Zhao, Jian-Zhu
    Han, Cheng-Bo
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [42] Brain metastases in patients with EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Karachaliou, Niki
    LANCET RESPIRATORY MEDICINE, 2017, 5 (09): : 669 - 671
  • [43] Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
    Cabanero, M.
    Tsao, M. S.
    CURRENT ONCOLOGY, 2018, 25 : S38 - S44
  • [44] The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Zhou, Fei
    Guo, Haoyue
    Xia, Yang
    Le, Xiuning
    Tan, Daniel S. W.
    Ramalingam, Suresh S.
    Zhou, Caicun
    NATURE REVIEWS CLINICAL ONCOLOGY, 2025, 22 (02) : 95 - 116
  • [45] Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
    Wu, Fang
    Liu, Xianling
    Ma, Jin-an
    Gao, Yawen
    Hu, Chunhong
    LANCET ONCOLOGY, 2018, 19 (03): : E124 - E124
  • [46] Targeting MET amplification in EGFR-mutant non-small-cell lung cancer
    Rosell, Rafael
    Chaib, Imane
    Santarpia, Mariacarmela
    LANCET RESPIRATORY MEDICINE, 2020, 8 (11): : 1068 - 1070
  • [47] Minimal residual disease in EGFR-mutant non-small-cell lung cancer
    Bain, Nathan T. T.
    Wang, Yang
    Arulananda, Surein
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [48] Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
    Wang, Shouzheng
    Li, Junling
    ONCOTARGETS AND THERAPY, 2019, 12 : 6535 - 6548
  • [49] FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer
    Gold, Kathryn A.
    Erasmus, Jeremy J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) : 1131 - 1132
  • [50] EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome
    Tiefenbacher, Andreas
    Pirker, Robert
    JOURNAL OF THORACIC DISEASE, 2017, 9 (11) : 4208 - 4211
12345